Comparative Assessment of Antianginal Efficacy and Safety of Nicorandil at the Background of Therapy With β-Adrenoblockers in Ischemic Heart Disease Patients With Stable Angina

Background: Ischemic heart disease (IHD) is one of the principle causes of morbidity and of mortality in women1. Ischemic heart disease may manifest clinically as either chronic stable angina or acute coronary syndrome2 (ACS). Traditional risk factors (hypertension, diabetes, etc.) contribute to the development of IHD in both women and men. Some risk factors are unique to women (e.g., pregnancy-related complications, menopause), which cause increased mortality in women Aim: To study the risk factors and clinical profile of ischemic heart disease in women. Materials And Methods: Hospital-based prospective, cross-sectional study done in 50 patients with ischemic heart disease. Patients with a history of Chest pain suggestive of ischemic heart diseases and Electrocardiogram and cardiac biomarkers suggestive of ischemic heart disease were included in the study. Results: Maximum incidence of ischemic heart diseases is seen in the 6th decade. Mean age is 58.92 + 2.8years. 64%of the patients presented with chest pain, and 36% patients presented without any chest pain. After chest pain, the most common symptom was palpitations, seen in 56% patients, followed by sweating (44%). 30% presented to the medical facility within 3hours. 88% were diagnosed with acute coronary syndrome, and 12% were diagnosed with chronic stable angina. Women specific risk factors include the pregnancy-related complications seen in 10% patients, menopause attained in 86% patients, PCOS seen in 08% patients, use of oral contraceptive pills noticed in 08% patients, Other risk factors identified were hypothyroidism in 16% patients, connective tissue disorders like rheumatoid arthritis seen in 12% of the patients. Conclusion: Awareness regarding atypical symptoms as well as other symptoms of IHD should be created among women to avoid delayed complications. Simple lifestyle modifications like physical activity, diet modifications, etc., will reduce the number of women at risk for IHD.

Download Full-text

Influence of koraksan treatment on vascular wall condition, immunology inflamation and heart rate variability and in patients with ischemic heart disease: stable angina pectoris II-III FC

I P Pavlov Russian Medical Biological Herald ◽

10.17816/pavlovj2009250-57 ◽

2009 ◽

Vol 17 (2) ◽

pp. 50

Author(s):

A V Prasolov ◽

M I Moskaluk ◽

L A Knyazeva

Keyword(s):

Heart Rate ◽

Heart Rate Variability ◽

Heart Disease ◽

Angina Pectoris ◽

Ischemic Heart Disease ◽

Stable Angina ◽

Vascular Wall ◽

Ischemic Heart ◽

Stable Angina Pectoris ◽

Wall Condition

Download Full-text

The effect of rivaroxaban low doses on the stable angina of the II–III functional class clinical manifestations and the quality of life in patients with ischemic heart disease

Kardiologiia ◽

10.18087/cardio.2021.9.n1696 ◽

2021 ◽

Vol 61 (9) ◽

pp. 47-51

Author(s):

A. A. Nekrasov ◽

E. S. Timoshchenko ◽

T. A. Nekrasova ◽

M. V. Timoshchenko ◽

A. V. Suleimanova

Keyword(s):

Quality Of Life ◽

Heart Disease ◽

Ischemic Heart Disease ◽

Acetylsalicylic Acid ◽

Stable Angina ◽

Clinical Manifestations ◽

Functional Class ◽

Ischemic Heart ◽

Short Acting

Aim To evaluate the effect of low-dose rivaroxaban on quality of life of patients and clinical manifestations of functional class (FC) II-III stable angina.Material and methods 26 patients with ischemic heart disease (IHD) with FC II-III stable angina, who were newly prescribed rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg, were followed for 10 weeks. During the first (before the beginning of treatment) and the last weeks of study, patients kept diaries, in which they reported angina attacks and short-acting nitrate intake, filled in an angina questionnaire (SAQ), and underwent electrocardiogram (ECG) Holter monitoring (HM).Results The treatment was associated with decreases in the frequency of angina attacks (by 19.5 %; р=0.027) and the number of taken short-acting nitrate pills (by 17.1 %; р=0.021) and an improvement of quality of life according to stability scales (р=0.042). Data from ECG HM showed decreases in the number and duration of ischemic episodes (p≤0.05).Conclusion The treatment of IHD patients with rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg for 2 mos. was associated with decreased frequency of angina attacks, reduced requirement for short-acting nitrate, and with improvement of quality of life.

Download Full-text